FarmavitaR+

1. Change of Access
(Regulatory Affairs/European Union)

Romania - Notice on change of access to information on centrally authorised medicinal products The NMA hereby informs you on replacement of PDF files in the “Useful Information” section of the main ...

2. NMA of Romania News Flash
(Regulatory Affairs/European Union)

Important notice to the attention of Marketing Authorisation Holders The NMA hereby informs you on certain issues of importance in the CMD(h) Press Release on the Report from the CMD(h) meeting ...

3. NMA of Romania News Flash
(Regulatory Affairs/European Union)

...  Romania - Important notice to the attention of Marketing Authorisation Holders The NMA hereby informs you on certain issues of importance in the ...

4. NMA of Romania News Flash
(Regulatory Affairs/European Union)

... X-NONE MicrosoftInternetExplorer4 Links to the EMEA website also enable consultation of European Public Assessment Reports (EPARs) centrally authorised medicinal products. The NMA also ...

5. NMA of Romania News Flash
(Regulatory Affairs/European Union)

National Medicines Agency of Romania NMA  News Flash To the attention of Marketing Authorisation Holders In view of updating the National Medicines Agency’s (NMA) data base concerning representatives ...

6. NMA of Romania News Flash
(Regulatory Affairs/European Union)

National Medicines Agency of Romania To the attention of Holders of Marketing Authorisations granted through centralised procedure Even though notification of the National Medicines Agency (NMA) ...

7. First FarmavitaR+ / regulanet conference
(Regulatory Affairs/Regulatory Affairs News)

... in training on regulanet core SOPs and received an introduction to R+ docuBridge SOPs. regulanet members from Denmark, Germany and the United Kingdom were joined at the conference by FvR+ ...

8. Administrative Fees - Romania
(Regulatory Affairs/European Union)

... depends on the type of the application (registration, variation by national procedure/ MRP/ DCP). Please find attached a list of fees for registration of medicinal products by NMA, depending on the ...

9. Hypertension Therapy and Market Report
(Reports/Market Report)

... arteriolar dialatation > t.p.r. decreases, BP falls. The direct depressant effect on heart requires much higher dose, but a weak negative inotropic action can be unmasked after B blockers. It does ...

10. Nanotubes Against Cancer
(Professional Articles/Life Science Article)

... J.F. (1999). Carbon Nanotubes and Related Structures. Cambridge, UK: Cambridge University Press. 33.   Inman, Mason. "Legendary Swords' Sharpness, Strength From Nanotubes, Study ...

11. Atorvastatin
(Pharmaceutical product/Pharmaceutical product)

... Malaysia seem to be a rather woolly area, Pfizer might not waste too much time in court there. This was not the case in Denmark, though, where Ranbaxy tried again. Ranbaxy launched a generic Atorvastatin ...

12. Drug Delivery
(Professional Articles/Life Science Article)

... so researchers are searching for effective methods of delivering intact, functional siRNA agents into tumor cells. Now, work from the iNANO Center at University of Aarhus, in Denmark, shows that sugar ...